News

Press Releases

December 15, 2020

NodThera Appoints Chief Medical Officer and Chief Financial Officer

Strengthens senior leadership team with appointments of Donald Johns, M.D., as Chief Medical Officer and Katina Dorton,…

Read more >

June 3, 2020

NodThera Announces Close of $55 Million Series B Financing

Financing round led by Novo Holdings and includes new investors Cowen Healthcare Investments and Sanofi Ventures, as…

Read more >

April 10, 2019

NodThera Highlights Significant Progress with Advancement of Lead Development Candidate and Key Additions to Board

– Company advances NT-0167 as first development candidate from a broad platform of NLRP3 inflammasome inhibitors –…

Read more >

December 15, 2020

NodThera Appoints Chief Medical Officer and Chief Financial Officer

Strengthens senior leadership team with appointments of Donald Johns, M.D., as Chief Medical Officer and Katina Dorton,…

Read more >

June 3, 2020

NodThera Announces Close of $55 Million Series B Financing

Financing round led by Novo Holdings and includes new investors Cowen Healthcare Investments and Sanofi Ventures, as…

Read more >

April 10, 2019

NodThera Highlights Significant Progress with Advancement of Lead Development Candidate and Key Additions to Board

– Company advances NT-0167 as first development candidate from a broad platform of NLRP3 inflammasome inhibitors –…

Read more >

October 23, 2018

NodThera announces the appointment of Alison Strutt PhD as Head of Finance & Operations, the launch of its new corporate office in Boston and the opening of its laboratory in Seattle

– Expansion in the US is consistent with NodThera’s strategy to access world class talent, foster collaborative…

Read more >

September 23, 2018

NodThera announces the appointment of Adam Keeney PhD as President and Chief Executive Officer

– Dr Keeney joins NodThera with over 20 years of pharmaceutical industry experience, including most recently at…

Read more >

June 25, 2018

NodThera secures £28 million ($40 million) Series A Financing

– NodThera discovers and develops next generation NLRP3 inflammasome inhibitors for the treatment of diseases driven by…

Read more >

July 28, 2016

Epidarex Capital Creates Nodthera Limited

A pioneering new company based on Selvita research and utilizing novel immunological approaches to disease Edinburgh, Scotland,…

Read more >

Media Contact

Matthew Corcoran
Ten Bridge Communications
(617) 866-7350

For all other company inquiries, contact us at info@nodthera.com.